-5%
Solifenacin is a competitive muscarinic receptor antagonist. It primarily targets M3, M1, and M2 receptors, with a high affinity for M3 receptors. By antagonizing the M3 receptor, Solifenacin prevents the contraction of the detrusor muscle, reducing bladder contractions and helping control symptoms of overactive bladder.
